Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome 2024-04-03 11:14
RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024 2024-03-11 10:36
World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap 2024-02-02 21:30
RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients 2024-01-12 18:17
RemeGen's Pioneering RC88 Receives IND Approval from US FDA for Platinum-Resistant Recurrent Ovarian Cancer Treatment 2023-12-28 15:45
RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients 2023-12-18 20:56
RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO) 2023-11-28 09:48
RemeGen to Present Telitacicept Phase III Clinical Trial Results for Rheumatoid Arthritis Patients in a Late-Breaking Abstract Oral Presentation Session at the American College of Rheumatology 2023-11-15 16:35
Remegen's Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis 2023-09-27 09:30
RemeGen's Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren's Syndrome: Findings Published in Prestigious Rheumatology Journal 2023-07-25 16:00
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the Potential of RC88 and RC108 Combined with PD-1 Therapy for Advanced Solid Tumors 2023-07-10 10:24
ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer 2023-06-05 21:26
RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name 2023-06-05 21:17
RemeGen Celebrates World Intellectual Property Day 2023 2023-04-26 10:00
On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy 2023-02-28 09:16
RemeGen's RC118 for Injection Targeting Claudin 18.2 in Patients with Gastric and Pancreatic Cancers Granted Two Orphan Drug Designations by U.S. FDA 2022-12-13 12:30
RemeGen's Disitamab Vedotin Achieves First-Line Treatment Recommendation Status for Advanced Urothelial Cancer in Updated 2022 CSCO Guidelines 2022-11-17 08:00
RemeGen Releases Phase II Clinical Study Data for Treatment of Myasthenia Gravis in Chinese Patients 2022-11-01 12:12
RemeGen Receives Orphan Drug Designation from FDA for Telitacicept for the Treatment of Myasthenia Gravis 2022-10-13 08:00
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China 2022-09-19 21:00
1 2